The need for a new strategy for the treatment of multiple sclerosis

Control of immune-mediated disease of the central nervous system with monoclonal (CD4-specific) antibodies.

Journal of neuroimmunology·1993

Isolation and characterization of cells infiltrating the spinal cord during the course of chronic relapsing experimental allergic encephalomyelitis in the Biozzi AB/H mouse.

Cellular immunology·1993

Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone.

Clinical and experimental immunology·1992

Therapy of chronic relapsing experimental allergic encephalomyelitis and the role of the blood-brain barrier: elucidation by the action of Brequinar sodium.

Journal of neuroimmunology·1992

Suppression of demyelination by mitoxantrone.

International journal of immunopharmacology·1991

Degradation of human myelin in vitro by leucocytes from patients with multiple sclerosis.

Clinical and experimental immunology·1990

Discriminating behavioral variant frontotemporal dementia from Alzheimer's disease via the Frontal Assessment Battery.

Journal of neurology·2026

The predictive value of serum neurofilament light chain levels beyond MRI measures for clinical and radiological disease progression in the earliest stages of multiple sclerosis.

Journal of neurology·2026

Convergent validity, responsiveness, and meaningful within-subject change of the PROM-Ataxia in spinocerebellar ataxias.

Journal of neurology·2026

Ofatumumab in multiple sclerosis: 2-year immune profiling and clinical correlates.

Journal of neurology·2026

Autoantibodies targeting G protein-coupled receptors and clinical outcome after ischemic stroke (PROSCIS-B).

Journal of neurology·2026

Timing of aneurysm repair and clinical outcomes after aneurysmal subarachnoid hemorrhage: a systematic review.

Journal of neurology·2026

Clinical Efficacy of High-Frequency Deep Repetitive Transcranial Magnetic Stimulation in the Treatment of Depression and the Predictive Role of Baseline Triglyceride Levels: A Randomized Sham-Controlled Trial.

Clinical EEG and neuroscience·2026

Mechanistic Basis and Therapeutic Potential of a Novel TXNIP Inhibitor in Diabetes Treatment.

Journal of medicinal chemistry·2026

Discovery of BRD9 PROTAC/IMiD Bifunctional Molecules as Potent Therapeutics for Hematologic Malignancies.

Journal of medicinal chemistry·2026

First line asciminib in chronic myeloid leukemia: a quest for the "Holy Grail" of tolerability.

Haematologica·2026

Successful treatment of systemic juvenile xanthogranuloma with an ABL2::GAB2 fusion using dasatinib after failure of conventional chemotherapy and MEK inhibition.

Haematologica·2026

Repurposing MK0873 as a non-covalent hTERT-Targeting compound: a proof of concept study.

Frontiers in aging·2026

Related Experiment Videos

The need for a new strategy for the treatment of multiple sclerosis

Related Concept Videos

Control of immune-mediated disease of the central nervous system with monoclonal (CD4-specific) antibodies.

Isolation and characterization of cells infiltrating the spinal cord during the course of chronic relapsing experimental allergic encephalomyelitis in the Biozzi AB/H mouse.

Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone.

Therapy of chronic relapsing experimental allergic encephalomyelitis and the role of the blood-brain barrier: elucidation by the action of Brequinar sodium.

Suppression of demyelination by mitoxantrone.

Degradation of human myelin in vitro by leucocytes from patients with multiple sclerosis.

Discriminating behavioral variant frontotemporal dementia from Alzheimer's disease via the Frontal Assessment Battery.

The predictive value of serum neurofilament light chain levels beyond MRI measures for clinical and radiological disease progression in the earliest stages of multiple sclerosis.

Convergent validity, responsiveness, and meaningful within-subject change of the PROM-Ataxia in spinocerebellar ataxias.

Ofatumumab in multiple sclerosis: 2-year immune profiling and clinical correlates.

Autoantibodies targeting G protein-coupled receptors and clinical outcome after ischemic stroke (PROSCIS-B).

Timing of aneurysm repair and clinical outcomes after aneurysmal subarachnoid hemorrhage: a systematic review.

Clinical Efficacy of High-Frequency Deep Repetitive Transcranial Magnetic Stimulation in the Treatment of Depression and the Predictive Role of Baseline Triglyceride Levels: A Randomized Sham-Controlled Trial.

Mechanistic Basis and Therapeutic Potential of a Novel TXNIP Inhibitor in Diabetes Treatment.

Discovery of BRD9 PROTAC/IMiD Bifunctional Molecules as Potent Therapeutics for Hematologic Malignancies.

First line asciminib in chronic myeloid leukemia: a quest for the "Holy Grail" of tolerability.

Successful treatment of systemic juvenile xanthogranuloma with an ABL2::GAB2 fusion using dasatinib after failure of conventional chemotherapy and MEK inhibition.

Repurposing MK0873 as a non-covalent hTERT-Targeting compound: a proof of concept study.

Related Experiment Videos

The need for a new strategy for the treatment of multiple sclerosis

Related Concept Videos

Related Articles